Q2 EPS Estimates for OPKO Health Reduced by Zacks Research

OPKO Health, Inc. (NASDAQ:OPK - Free Report) - Equities researchers at Zacks Research decreased their Q2 2025 earnings estimates for OPKO Health in a research report issued to clients and investors on Wednesday, May 21st. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings per share of ($0.09) for the quarter, down from their previous estimate of ($0.07). The consensus estimate for OPKO Health's current full-year earnings is ($0.25) per share. Zacks Research also issued estimates for OPKO Health's Q3 2025 earnings at ($0.09) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.37) EPS, Q1 2026 earnings at ($0.08) EPS, Q2 2026 earnings at ($0.07) EPS, Q3 2026 earnings at ($0.07) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.29) EPS, Q1 2027 earnings at ($0.05) EPS and FY2027 earnings at ($0.11) EPS.

OPKO Health (NASDAQ:OPK - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $163.13 million. OPKO Health had a negative net margin of 18.65% and a negative return on equity of 9.76%. The firm's revenue for the quarter was down 13.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.12) EPS.

Other equities research analysts also recently issued research reports about the stock. JPMorgan Chase & Co. assumed coverage on shares of OPKO Health in a research note on Friday, April 25th. They issued a "neutral" rating for the company. Wall Street Zen cut shares of OPKO Health from a "hold" rating to a "sell" rating in a research note on Monday, May 5th. HC Wainwright reiterated a "buy" rating and issued a $3.00 price objective on shares of OPKO Health in a research note on Monday, April 7th. Finally, Barrington Research reiterated an "outperform" rating and issued a $2.25 price objective on shares of OPKO Health in a research note on Thursday, May 1st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average price target of $2.75.

OPKO Health Price Performance

NASDAQ:OPK traded down $0.01 on Monday, reaching $1.36. The stock had a trading volume of 513,789 shares, compared to its average volume of 3,883,873. OPKO Health has a 1-year low of $1.19 and a 1-year high of $2.04. The stock has a fifty day moving average price of $1.42 and a 200-day moving average price of $1.54. The company has a market capitalization of $1.07 billion, a P/E ratio of -7.13 and a beta of 1.42. The company has a quick ratio of 2.69, a current ratio of 2.97 and a debt-to-equity ratio of 0.30.

Institutional Investors Weigh In On OPKO Health

Institutional investors have recently added to or reduced their stakes in the business. Sculptor Capital LP purchased a new stake in OPKO Health in the first quarter worth $21,111,000. Graham Capital Management L.P. raised its stake in OPKO Health by 214.7% during the first quarter. Graham Capital Management L.P. now owns 1,810,392 shares of the biotechnology company's stock valued at $3,005,000 after purchasing an additional 3,388,292 shares in the last quarter. Millennium Management LLC grew its holdings in shares of OPKO Health by 85.3% in the fourth quarter. Millennium Management LLC now owns 4,588,526 shares of the biotechnology company's stock worth $6,745,000 after purchasing an additional 2,112,382 shares during the last quarter. Lazard Asset Management LLC grew its holdings in OPKO Health by 143.6% during the 4th quarter. Lazard Asset Management LLC now owns 2,548,667 shares of the biotechnology company's stock worth $3,746,000 after acquiring an additional 1,502,342 shares in the last quarter. Finally, Altshuler Shaham Ltd bought a new stake in shares of OPKO Health in the 4th quarter valued at about $2,082,000. 64.63% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, CEO Phillip Md Et Al Frost bought 125,000 shares of the company's stock in a transaction that occurred on Thursday, April 10th. The shares were bought at an average price of $1.36 per share, for a total transaction of $170,000.00. Following the transaction, the chief executive officer now directly owns 214,001,448 shares of the company's stock, valued at approximately $291,041,969.28. The trade was a 0.06% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders have acquired 700,000 shares of company stock valued at $1,123,000 in the last ninety days. 49.69% of the stock is currently owned by insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.